# A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

> **NCT06401330** · PHASE3 · RECRUITING · sponsor: **Children's Oncology Group** · enrollment: 1656 (estimated)

## Conditions studied

- Stage I Mixed Cell Type Kidney Wilms Tumor
- Stage II Mixed Cell Type Kidney Wilms Tumor
- Stage III Mixed Cell Type Kidney Wilms Tumor
- Stage IV Mixed Cell Type Kidney Wilms Tumor

## Interventions

- **PROCEDURE:** Bone Scan
- **DRUG:** Carboplatin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Dactinomycin
- **DRUG:** Doxorubicin
- **DRUG:** Etoposide
- **DRUG:** Irinotecan
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Nephrectomy
- **OTHER:** Patient Observation
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Ultrasound Imaging
- **DRUG:** Vincristine
- **PROCEDURE:** X-Ray Imaging

## Key facts

- **NCT ID:** NCT06401330
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2031-02-13
- **Final completion:** 2031-02-13
- **Target enrollment:** 1656 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06401330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06401330, "A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06401330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*